Key Takeaways Researchers at MUSC report that engineered mesenchymal stem cells reversed new-onset type 1 diabetes in mice, pointing to the disease’s immune response rather than just its symptoms. The cells were modified to overexpress a protein called alpha-1 antitrypsin, which calmed the autoimmune attack and protected insulin producing beta
Key Takeaways Stem cell therapy can slow cellular aging by targeting the immune system dysfunction and chronic inflammation that drive the aging process at the cellular level. Growth factors released by mesenchymal stem cells (MSCs) support boosting collagen, repairing damaged tissue, and improving skin quality from within. Findings show improvements
Key Takeaways Umbilical cord derived mesenchymal stem cells (UC-MSCs) are a well-studied source of MSC therapy for ulcerative colitis UC, with strong anti-inflammatory and tissue repair properties. UC-MSCs home to inflamed tissue, calm overactive immune cells, and promote macrophage repolarisation from a damaging M1 state to a healing M2 state.
Key Takeaways The realistic goals of stem cell therapy for MS are slowing disease activity, reducing fatigue, and improving mobility, not reversing all past damage. Mesenchymal stem cells (MSCs) calm the immune system and protect nerve fibers. Hematopoietic stem cell transplant (HSCT) goes further, aiming to reset the immune system
Quick Summary Family support is essential for recovery after cell-based therapy for hypoxic brain damage. Families help with daily rehabilitation exercises, motor function practice, medication schedules, and emotional support. Recovery takes months or years, and consistent family involvement improves both short-term and long-term neurological outcomes alongside treatments like mesenchymal stem
Quick Summary New 2026 Phase 2 data for BRTX-100 (autologous mesenchymal stem cell therapy for chronic lumbar disc disease) shows sustained pain and functional improvements at 52 weeks: 56% of evaluable patients had ≥50% VAS pain reduction, 64% had ≥50% ODI disability improvement. Safety data reported no dose-limiting toxicities or
Quick Summary Stem cell therapy is making measured progress toward treating age-related diseases like vision loss, frailty, and Parkinson’s, but broad age reversal remains unproven. Recent clinical trials show improved mobility in frailty patients, while Parkinson’s and vision repair trials aim to replace specific damaged cells. However, safety risks persist,
Quick Summary Mesenchymal stem cell (MSC) therapy for IBD (Crohn’s disease and ulcerative colitis) reduces inflammation, supports repair of damaged intestinal tissue, and helps balance immune response. It is not a replacement for biologics or steroids but may work alongside them. Clinical trials show improved gut symptoms and mucosal healing
Quick Summary Mesenchymal stem cells (MSCs) help regulate immune responses in relapsing-remitting MS by interacting with immune cells, reducing inflammation, and providing neuroprotective effects. Unlike traditional immunosuppressive treatments, MSCs promote balanced immune modulation and may offer long-term stability with a favorable safety profile. How MSCs work: Interact with T cells
Quick Read Summary Research Findings Clinical trials show that mesenchymal stem cells, kidney stem cells, and stem cell derived therapies may support kidney repair. Early results indicate slower progression of CKD, reduced inflammation, and improved kidney function. Results vary depending on stem cell type, dosage, and delivery method. Key Points
